10 Fastest Growing Penny Stocks to Buy Now

3. Geron Corporation (NASDAQ:GERN)

3-Year Sales Growth: 280.92%

Sales Growth Year over Year: 522.13%

Stock Upside Potential: 273.83%

Number of Hedge Fund Holders: 37

Geron Corporation (NASDAQ:GERN) is one of the fastest-growing penny stocks to buy now. On November 11 at the Stifel 2025 Healthcare Conference, it reiterated plans to overcome challenges as it seeks to enhance the commercialization of Rytelo, a prescription medication used to treat anemia.

The company plans to shift Rytelo’s use to earlier treatment lines. Part of the plan entails positioning the candidate drug for earlier use in the treatment setting, especially as a second-line therapy. Geron is to implement a surround-sound approach that will increase physician awareness and engagement. While the drug’s sales stagnated in 2025 at about $50 million, the company is optimistic of significant growth in 2026.

Amid the proposed sales plans for Rytelo, Needham analyst Gil Blum has reiterated a Buy rating and set a $4 price target. On the other hand, Leerink Partners reiterated an Outperform rating on the stock on November 5 but cut the price target to $2 from $3. Leerink reaffirmed an outperform rating, expecting the company to take the necessary steps to improve Rytelo’s performance, including expanding its field force.

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing medicines to treat blood cancers, specifically myeloid hematologic malignancies. Its main product, RYTELO (imetelstat), is an approved telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes, and the company is researching its use in other blood cancers.